Form 4: Quest Diagnostics Director Acquires Shares
Statement of Changes in Beneficial Ownership
Quest Diagnostics Director Denise M. Morrison acquired 1,142 shares of common stock through an award of restricted stock units.
Summary
- Denise M. Morrison, a Director at Quest Diagnostics Inc., acquired 1,142 shares of common stock on May 20, 2026.
- The acquisition was made through an award of restricted stock units (RSUs).
- Following this transaction, Morrison beneficially owns 11,929 shares of common stock.
- The reported amount includes shares acquired via dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine equity award and acquisition by a director, with no immediate indication of significant positive or negative company performance.
Positives
- Director Denise M. Morrison has increased her direct beneficial ownership of Quest Diagnostics common stock.
- The acquisition of shares through RSUs indicates a form of equity-based compensation, aligning director interests with the company's performance.
- Dividend reinvestment further enhances the director's stake in the company over time.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing.
Industry Context
StockSavvy.ai notes that insider transactions, such as this acquisition of shares by a director, are common disclosures in the healthcare diagnostics sector. These filings provide transparency into management's confidence and investment in their own company.
Stakeholder Impact
- Shareholders: Increased director ownership can be seen as a positive signal of commitment to the company's long-term success.
- Employees: The transaction does not directly impact employees but reflects the company's compensation structure for its board.
- Creditors: No direct impact on creditors is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Transaction Date for acquisition of common stock. |
| 05/21/2026 | Signature Date of the filing. |
Keywords
Quest Diagnostics, DGX, Form 4, Insider Trading, Restricted Stock Units, Director, Beneficial Ownership, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.